The Expression And Clinical Significance Of RhoB And E-cadherin In Non-Small Cell Lung Cancer Tissues

ObjectiveTo investigate expression of RhoB and E-cadherin in Non-Small Cell Lung Cancer (NSCLC) and their clinical significances.MethodsTo collect116cases of patients with NSCLC who had surgery in Tianjin Chest Hospital during January to December in2008. Immunohistochemical staining was applied to detect different expression of RhoB and E-cadherin in NSCLC group (116cases) and control group(116cases). Correlations of expression of RhoB and E-cadherin to clinical pathological parameters and prognosis and their correlations were analysed.Results(1) The expression intensities of RhoB and E-cadherin in NSCLC were distinctly lower than those in control group(P<0.01).(2) The expression of RhoB and E-cadherin in NSCLC was not significantly different in sex, smoking, tumor location and tumor size. The expression of RhoB in NSCLC was significantly different in pathological type, differentiation and lymph node metastasis. The expression of E-cadherin in NSCLC was significantly different in TNM stage, differentiation and lymph node metastasis.(3) The expression of RhoB and E-cadherin in NSCLC demonstrated significantly positive relation(r=0.503, P<0.01).(4) The3-year survival rates were higher in patients with RhoB high expression(83.93%) than those with low expression(40.00%), while the3-year survival rates were higher in patients with E-cadherin high expression(85.11%) than those with low expression (44.93%). Furthermore, the3-year survival rates were higher in patients with both RhoB and E-cadherin high expression than those with both RhoB and E-cadherin low expression.(5) Further multivariate analysis suggested that both low expression of RhoB and E-cadherin and lymph node metastasis were prognostic indicators for NSCLC.ConclusionThe expression intensities of RhoB and E-cadherin in NSCLC were low. The expression of RhoB and E-cadherin in NSCLC was not significantly different in sex, smoking, tumor location and tumor size. The expression of RhoB in NSCLC was significantly different in pathological type, differentiation and lymph node metastasis. The expression of E-cadherin in NSCLC was significantly different in TNM stage, differentiation and lymph node metastasis. The3-year survival rates were higher in patients with RhoB high expression, while the3-year survival rates were higher in patients with E-cadherin high expression. Furthermore, the3-year survival rates were higher in patients with both RhoB and E-cadherin high expression than those with both RhoB and E-cadherin low expression. Both low expression of RhoB and E-cadherin and lymph node metastasis were prognostic indicators for NSCLC. The expression of RhoB and E-cadherin shows a good correlation in NSCLC. Detecting the expression of RhoB combined with E-cadherin in NSCLC tissue may give a clue on prognosis of patient.